| P/E (FY) | — | Sales (TTM) | $1.13B |
| Earnings (TTM) | -$309.4M | ROE | −42.49% |
| Net Margin | −30.08% | ROIC | — |
| Debt / Equity | 0.56 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
| Market Cap | $12.42B | Trading Days | 4894 |
| 52W High | 615.00 |
| 52W Low | 286.44 |
| % Off High | −12.39% |
| YTD | −7.48% | 1Y | 83.17% |
| 3Y | 162.18% | 5Y | 507.30% |
| 10Y | 6763.69% | Since incept. (ann.) | 2.82% |
Reportable 100%
| Ann. Volatility (1Y) | 43.82% | Ann. Volatility (3Y) | 55.53% |
| Sharpe (1Y) | 1.63 | Sharpe (3Y) | 0.88 |
| Max Drawdown (1Y) | −29.36% | Max Drawdown (3Y) | −41.41% |
| Beta (3Y, vs SPY) | 1.59 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ELAN | Elanco Animal Health Inc | $12.75B | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $12.08B | — |
| AXSM | Axsome Therapeutics, Inc. | $12.05B | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $12.00B | 34.5 |
| QNRX | Quoin Pharmaceuticals, Ltd. | $14.09B | — |
| GPCR | Structure Therapeutics Inc. | $10.21B | — |
| CORT | CORCEPT THERAPEUTICS INC | $10.11B | 114.9 |
| SMMT | Summit Therapeutics Inc. | $10.01B | — |
| CYTK | CYTOKINETICS INC | $9.89B | — |
| JAZZ | Jazz Pharmaceuticals plc | $16.12B | — |
| BBIO | BridgeBio Pharma, Inc. |
| $16.76B |
| — |
| IONS | IONIS PHARMACEUTICALS INC | $9.14B | — |
